NRAS and melanoma: Intriguingly, KIT (1.97% of cases) and NRAS (0.66% of cases) were detected as drivers (p = 2E-4 and 9E-4, respectively; Additional files 11 and 12) where KIT is mutated in melanomas, gastrointestinal stromal tumors, adult acute myeloid leukemia patients, and many other tumor types at high frequency and is the target of the kinase inhibitor Imatinib.